Cabometyx take control briefing guide lr pdf
Os logo

CABOMETYX is the only single-agent TKI to demonstrate an overall survival benefit in 2L aRCC

Median OS: 21.4 vs. 17.1 months everolimus
(HR = 0.70, 95% CI: 0.58-0.85); p = 0.000233

Learn more
Manageable tolerability profile

Manageable tolerability profile

Proven across clinical trials6,33,34,40

Learn more
Independent validation

Independent validation

Validated and recommended by major (inter)national guidelines32,44-47

Learn more

Leer meer over CABOMETYX en hoe het u en uw patiënten kan helpen in 2L aRCC

*In a Phase 3, randomised, open-label study comparing CABOMETYX (n=330) with everolimus (n=328) in adult patients with aRCC progressing after prior anti-VEGF therapy.33

CABOMETYX is indicated for the treatment of advanced renal cell carcinoma (RCC)6:

  • in treatment-naïve adults with intermediate or poor risk per IMDC criteria
  • in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.

1L: First-Line, 2L: Second-Line, CI: Confidence Interval, HR: Hazard Ratio, IMDC: International Metastatic Renal Cell Carcinoma Database, OS: Overall Survival, TKI: Tyrosine Kinase Inhibitor.